Cravath, Swaine & Moore LLP Logo
  • Practices
  • People
  • Careers
  • News & Insights
  • Practices
  • People
  • Careers
  • News & Insights
  • Our Story
  • The Cravath System
  • Diversity & Inclusion
  • Pro Bono
  • Alumni Journal
  • 200.Cravath

Cravath’s London Office Moves to 100 Cheapside

Read More

People

Jin-Kyu
Baek

Partner, Corporate

jbaek@cravath.com
  • New York+1-212-474-1408
    • E-mail
    • Twitter
    • Facebook
    • LinkedIn
  • PDF
  • Vcard
  • Overview
  • Credentials
  • Featured Work
  • News & Insights

Jin-Kyu Baek focuses his practice on mergers and acquisitions, corporate governance and general corporate matters. He has advised public and private companies, as well as boards of directors and special committees, in connection with a variety of significant transactions.

Mr. Baek’s notable matters include representing:

  • Disney in its $85 billion acquisition of 21st Century Fox;
  • Kenvue in its pending $48.7 billion acquisition by Kimberly‑Clark and its cooperation agreement with Starboard;
  • Viacom’s transaction committee in the $30 billion merger with CBS;
  • The special committee of the board of directors of EchoStar in the $26 billion combination with DISH Network;
  • Johnson & Johnson in its $16.6 billion acquisition of Abiomed, its $14.6 billion acquisition of Intra‑Cellular Therapies, its $6.5 billion acquisition of Momenta, its pending $3.05 billion acquisition of Halda Therapeutics, the $2.1 billion sale of LifeScan to Platinum Equity, its $2 billion acquisition of Ambrx and Janssen’s $750 million acquisition of bermekimab from XBiotech;
  • CyrusOne in its $15 billion acquisition by KKR and Global Infrastructure Partners;
  • Aon in its $13 billion acquisition of NFP;
  • Amazon in its $8.45 billion acquisition of MGM;
  • AmerisourceBergen in its $6.5 billion acquisition of Walgreens’ Alliance Healthcare businesses;
  • Cano Health shareholders, including members of management, in the $4.4 billion SPAC merger with Jaws Acquisition Corp., including an $800 million PIPE investment;
  • Thermo Fisher Scientific in its $3.1 billion acquisition of Olink;
  • Consolidated Communications’ special committee in the $3.1 billion acquisition by Searchlight and BCI;
  • Radius Global Infrastructure in its $3 billion acquisition by EQT Active Core Infrastructure and PSP Investments;
  • Roivant Sciences in its $3 billion Strategic Alliance with Sumitomo Dainippon Pharma;
  • IBM in its €2.13 billion acquisition of the StreamSets and webMethods platforms from Software AG;
  • Star Bulk in its $2.1 billion combination with Eagle Bulk Shipping;
  • FactSet in its $1.925 billion acquisition of CUSIP Global Services from S&P Global, its $246.5 million acquisition of LiquidityBook and its acquisition of Irwin;
  • OneBeacon Insurance and White Mountains Insurance in the $1.7 billion sale of OneBeacon Insurance to Intact Financial;
  • Ashland in the $1.65 billion sale of its performance adhesives business to Arkema and the sale of its nutraceuticals business to Turnspire Capital Partners;
  • ADT in its $1.2 billion equity investment from State Farm;
  • Sobi in its $915 million acquisition of Dova;
  • Light & Wonder in its $850 million acquisition of Grover Charitable Gaming;
  • Pitney Bowes in the $700 million sale of its Software Solutions business to Syncsort;
  • Prosus in its $500 million PIPE investment in connection with Churchill II SPAC’s $1.5 billion merger with Skillsoft and acquisition of Global Knowledge;
  • US Foods in its $500 million convertible preferred equity investment from KKR;
  • BAF in Lindsay Goldberg’s sale of BAF to Madison IAQ;
  • Costamare in the spin-off of Costamare Bulkers;
  • Evergy in its agreements with Elliott Management and Bluescape Energy Partners;
  • GasLog Ltd. in its acquisition of GasLog Partners and its take‑private transaction with BlackRock’s Global Energy & Power Infrastructure Fund;
  • J.D. Power in its sale to Thoma Bravo;
  • Jefferies in the significant expansion of its Global Strategic Alliance with SMBC Group—which includes a joint venture combining their Japanese equities and ECM businesses, and an increase in SMBC’s equity ownership in Jefferies to up to 20%—and in the previous expansion that included a total commitment of up to $3.4 billion to Jefferies by SMBC;
  • KKR’s board committee in KKR’s conversion to a corporation; 
  • Montana Technologies in its joint venture with GE Vernova; and 
  • Univision in its sale of a majority stake to Searchlight and ForgeLight.

Mr. Baek has been included among Bloomberg Law’s “40 Under 40” in 2025 and he has been recognized for his work in mergers and acquisitions by IFLR1000. He has also been recognized by Lawdragon as among the “500 Leading Lawyers in America” and the “500 Leading Dealmakers in America.”

Mr. Baek is from Seoul, Republic of Korea. He received an A.B. cum laude from Harvard College in 2008 and a J.D. from Harvard Law School in 2015.

Mr. Baek joined Cravath in 2015 and was elected a partner in 2022. Prior to joining Cravath, he served as an officer in the Republic of Korea Air Force, including at the Air Force Operations Command and the Ministry of National Defense.

Mr. Baek’s notable matters include representing:

  • Disney in its $85 billion acquisition of 21st Century Fox;
  • Kenvue in its pending $48.7 billion acquisition by Kimberly‑Clark and its cooperation agreement with Starboard;
  • Viacom’s transaction committee in the $30 billion merger with CBS;
  • The special committee of the board of directors of EchoStar in the $26 billion combination with DISH Network;
  • Johnson & Johnson in its $16.6 billion acquisition of Abiomed, its $14.6 billion acquisition of Intra‑Cellular Therapies, its $6.5 billion acquisition of Momenta, its pending $3.05 billion acquisition of Halda Therapeutics, the $2.1 billion sale of LifeScan to Platinum Equity, its $2 billion acquisition of Ambrx and Janssen’s $750 million acquisition of bermekimab from XBiotech;
  • CyrusOne in its $15 billion acquisition by KKR and Global Infrastructure Partners;
  • Aon in its $13 billion acquisition of NFP;
  • Amazon in its $8.45 billion acquisition of MGM;
  • AmerisourceBergen in its $6.5 billion acquisition of Walgreens’ Alliance Healthcare businesses;
  • Cano Health shareholders, including members of management, in the $4.4 billion SPAC merger with Jaws Acquisition Corp., including an $800 million PIPE investment;
  • Thermo Fisher Scientific in its $3.1 billion acquisition of Olink;
  • Consolidated Communications’ special committee in the $3.1 billion acquisition by Searchlight and BCI;
  • Radius Global Infrastructure in its $3 billion acquisition by EQT Active Core Infrastructure and PSP Investments;
  • Roivant Sciences in its $3 billion Strategic Alliance with Sumitomo Dainippon Pharma;
  • IBM in its €2.13 billion acquisition of the StreamSets and webMethods platforms from Software AG;
  • Star Bulk in its $2.1 billion combination with Eagle Bulk Shipping;
  • FactSet in its $1.925 billion acquisition of CUSIP Global Services from S&P Global, its $246.5 million acquisition of LiquidityBook and its acquisition of Irwin;
  • OneBeacon Insurance and White Mountains Insurance in the $1.7 billion sale of OneBeacon Insurance to Intact Financial;
  • Ashland in the $1.65 billion sale of its performance adhesives business to Arkema and the sale of its nutraceuticals business to Turnspire Capital Partners;
  • ADT in its $1.2 billion equity investment from State Farm;
  • Sobi in its $915 million acquisition of Dova;
  • Light & Wonder in its $850 million acquisition of Grover Charitable Gaming;
  • Pitney Bowes in the $700 million sale of its Software Solutions business to Syncsort;
  • Prosus in its $500 million PIPE investment in connection with Churchill II SPAC’s $1.5 billion merger with Skillsoft and acquisition of Global Knowledge;
  • US Foods in its $500 million convertible preferred equity investment from KKR;
  • BAF in Lindsay Goldberg’s sale of BAF to Madison IAQ;
  • Costamare in the spin-off of Costamare Bulkers;
  • Evergy in its agreements with Elliott Management and Bluescape Energy Partners;
  • GasLog Ltd. in its acquisition of GasLog Partners and its take‑private transaction with BlackRock’s Global Energy & Power Infrastructure Fund;
  • J.D. Power in its sale to Thoma Bravo;
  • Jefferies in the significant expansion of its Global Strategic Alliance with SMBC Group—which includes a joint venture combining their Japanese equities and ECM businesses, and an increase in SMBC’s equity ownership in Jefferies to up to 20%—and in the previous expansion that included a total commitment of up to $3.4 billion to Jefferies by SMBC;
  • KKR’s board committee in KKR’s conversion to a corporation; 
  • Montana Technologies in its joint venture with GE Vernova; and 
  • Univision in its sale of a majority stake to Searchlight and ForgeLight.

Mr. Baek has been included among Bloomberg Law’s “40 Under 40” in 2025 and he has been recognized for his work in mergers and acquisitions by IFLR1000. He has also been recognized by Lawdragon as among the “500 Leading Lawyers in America” and the “500 Leading Dealmakers in America.”

Mr. Baek is from Seoul, Republic of Korea. He received an A.B. cum laude from Harvard College in 2008 and a J.D. from Harvard Law School in 2015.

Mr. Baek joined Cravath in 2015 and was elected a partner in 2022. Prior to joining Cravath, he served as an officer in the Republic of Korea Air Force, including at the Air Force Operations Command and the Ministry of National Defense.

Education

  • J.D., 2015, Harvard Law School
  • A.B., 2008, Harvard College
    cum laude

Admitted In

  • New York

Rankings

Bloomberg Law

  • They’ve Got Next: The 40 Under 40 (2025)

IFLR1000

  • Mergers and Acquisitions - US (2025)

Lawdragon

  • 500 Leading Lawyers in America (2025)
  • 500 Leading Dealmakers in America (2025, 2024)
  • 500 X – The Next Generation (2025, 2024, 2023)

Deals & Cases

November 17, 2025

Johnson & Johnson’s $3.05 Billion Acquisition of Halda Therapeutics OpCo, Inc.

On November 17, 2025, Johnson & Johnson announced it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc., a clinical‑stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTACTM) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. Cravath is representing Johnson & Johnson in connection with the transaction.

Deals & Cases

November 03, 2025

Kenvue’s $48.7 Billion Acquisition by Kimberly‑Clark

On November 3, 2025, Kenvue Inc. (“Kenvue”), a global consumer health leader, and Kimberly‑Clark Corporation (“Kimberly‑Clark”), a global personal care leader, announced an agreement under which Kimberly‑Clark will acquire all of the outstanding shares of Kenvue common stock in a cash and stock transaction that values Kenvue at an enterprise value of approximately $48.7 billion, based on the closing price of Kimberly‑Clark common stock on October 31, 2025. Under the terms of the agreement, which has been unanimously approved by each company’s Board of Directors, Kenvue shareholders will receive $3.50 per share in cash as well as 0.14625 Kimberly‑Clark shares for each Kenvue share held at closing. Upon closing of the transaction, current Kenvue shareholders are expected to own approximately 46% and current Kimberly‑Clark shareholders are expected to own approximately 54% of the combined company on a fully diluted basis. Cravath is representing Kenvue in connection with the transaction.

Deals & Cases

September 22, 2025

Jefferies and SMBC Group’s Significant Expansion of Global Strategic Alliance

On September 19, 2025, Jefferies Financial Group, Inc. (“Jefferies”) and Sumitomo Mitsui Financial Group, Inc., Sumitomo Mitsui Banking Corporation and SMBC Nikko Securities Inc. (collectively, “SMBC Group”) announced they are significantly expanding their Global Strategic Alliance. This will include a joint venture to combine their Japanese equities and ECM businesses. As part of this expansion, SMBC intends to increase its equity ownership in Jefferies to up to 20% in the open market. Cravath is representing Jefferies in connection with the transactions.

Deals & Cases

May 07, 2025

Costamare’s Spin‑Off of Costamare Bulkers

On May 7, 2025, Costamare Inc. (“Costamare”) announced that it has completed the spin‑off of its dry bulk business into a standalone public company, Costamare Bulkers Holdings Limited (“Costamare Bulkers”). Each holder of Costamare common shares received one common share of Costamare Bulkers for every five Costamare common shares held as of the close of business on April 29, 2025. Cravath represented Costamare in connection with the transaction.

Deals & Cases

February 18, 2025

Light & Wonder’s Acquisition of Grover Gaming’s Charitable Gaming Assets

On February 18, 2025, Light & Wonder, Inc. (“Light & Wonder”), the leading cross‑platform global games company, announced that it has entered into a definitive agreement to acquire the charitable gaming assets of Grover Gaming, Inc. and G2 Gaming, Inc. (together, “Grover Gaming”), a leading provider of electronic pull‑tabs for charitable gaming in the U.S., for total consideration of $850 million cash, subject to customary purchase price adjustments, and a four‑year revenue based earn‑out of up to $200 million cash. Cravath is representing Light & Wonder in connection with the transaction.

Activities

August 21, 2025

Jin Baek Featured in Bloomberg Law’s 2025 “They’ve Got Next: 40 Under 40” Series

On August 12, 2025, Cravath partner Jin‑Kyu Baek was featured in Bloomberg Law’s “They’ve Got Next: 40 Under 40” series, which recognizes young lawyers who are “raising the bar in the legal profession,” based on their work on key client matters, assumption of leadership roles, pro bono commitments and more.

Activities

April 17, 2024

Jin-Kyu Baek Named a 2024 LCLD Fellow

Cravath partner Jin‑Kyu Baek was selected to join the 2024 Leadership Council on Legal Diversity (LCLD) Fellows Program. The LCLD, which was founded in 2009 as an organization of chief legal officers and law firm managing partners committed to creating a more diverse and inclusive legal profession, selects attorneys “who have shown promising leadership potential” to participate in the Fellows Program, which is a year‑long, multi‑tiered professional development series that involves personal development opportunities, leadership training, and relationship‑building resources.

Jin-Kyu Baek focuses his practice on mergers and acquisitions, corporate governance and general corporate matters. He has advised public and private companies, as well as boards of directors and special committees, in connection with a variety of significant transactions.

Mr. Baek’s notable matters include representing:

  • Disney in its $85 billion acquisition of 21st Century Fox;
  • Kenvue in its pending $48.7 billion acquisition by Kimberly‑Clark and its cooperation agreement with Starboard;
  • Viacom’s transaction committee in the $30 billion merger with CBS;
  • The special committee of the board of directors of EchoStar in the $26 billion combination with DISH Network;
  • Johnson & Johnson in its $16.6 billion acquisition of Abiomed, its $14.6 billion acquisition of Intra‑Cellular Therapies, its $6.5 billion acquisition of Momenta, its pending $3.05 billion acquisition of Halda Therapeutics, the $2.1 billion sale of LifeScan to Platinum Equity, its $2 billion acquisition of Ambrx and Janssen’s $750 million acquisition of bermekimab from XBiotech;
  • CyrusOne in its $15 billion acquisition by KKR and Global Infrastructure Partners;
  • Aon in its $13 billion acquisition of NFP;
  • Amazon in its $8.45 billion acquisition of MGM;
  • AmerisourceBergen in its $6.5 billion acquisition of Walgreens’ Alliance Healthcare businesses;
  • Cano Health shareholders, including members of management, in the $4.4 billion SPAC merger with Jaws Acquisition Corp., including an $800 million PIPE investment;
  • Thermo Fisher Scientific in its $3.1 billion acquisition of Olink;
  • Consolidated Communications’ special committee in the $3.1 billion acquisition by Searchlight and BCI;
  • Radius Global Infrastructure in its $3 billion acquisition by EQT Active Core Infrastructure and PSP Investments;
  • Roivant Sciences in its $3 billion Strategic Alliance with Sumitomo Dainippon Pharma;
  • IBM in its €2.13 billion acquisition of the StreamSets and webMethods platforms from Software AG;
  • Star Bulk in its $2.1 billion combination with Eagle Bulk Shipping;
  • FactSet in its $1.925 billion acquisition of CUSIP Global Services from S&P Global, its $246.5 million acquisition of LiquidityBook and its acquisition of Irwin;
  • OneBeacon Insurance and White Mountains Insurance in the $1.7 billion sale of OneBeacon Insurance to Intact Financial;
  • Ashland in the $1.65 billion sale of its performance adhesives business to Arkema and the sale of its nutraceuticals business to Turnspire Capital Partners;
  • ADT in its $1.2 billion equity investment from State Farm;
  • Sobi in its $915 million acquisition of Dova;
  • Light & Wonder in its $850 million acquisition of Grover Charitable Gaming;
  • Pitney Bowes in the $700 million sale of its Software Solutions business to Syncsort;
  • Prosus in its $500 million PIPE investment in connection with Churchill II SPAC’s $1.5 billion merger with Skillsoft and acquisition of Global Knowledge;
  • US Foods in its $500 million convertible preferred equity investment from KKR;
  • BAF in Lindsay Goldberg’s sale of BAF to Madison IAQ;
  • Costamare in the spin-off of Costamare Bulkers;
  • Evergy in its agreements with Elliott Management and Bluescape Energy Partners;
  • GasLog Ltd. in its acquisition of GasLog Partners and its take‑private transaction with BlackRock’s Global Energy & Power Infrastructure Fund;
  • J.D. Power in its sale to Thoma Bravo;
  • Jefferies in the significant expansion of its Global Strategic Alliance with SMBC Group—which includes a joint venture combining their Japanese equities and ECM businesses, and an increase in SMBC’s equity ownership in Jefferies to up to 20%—and in the previous expansion that included a total commitment of up to $3.4 billion to Jefferies by SMBC;
  • KKR’s board committee in KKR’s conversion to a corporation; 
  • Montana Technologies in its joint venture with GE Vernova; and 
  • Univision in its sale of a majority stake to Searchlight and ForgeLight.

Mr. Baek has been included among Bloomberg Law’s “40 Under 40” in 2025 and he has been recognized for his work in mergers and acquisitions by IFLR1000. He has also been recognized by Lawdragon as among the “500 Leading Lawyers in America” and the “500 Leading Dealmakers in America.”

Mr. Baek is from Seoul, Republic of Korea. He received an A.B. cum laude from Harvard College in 2008 and a J.D. from Harvard Law School in 2015.

Mr. Baek joined Cravath in 2015 and was elected a partner in 2022. Prior to joining Cravath, he served as an officer in the Republic of Korea Air Force, including at the Air Force Operations Command and the Ministry of National Defense.

Mr. Baek’s notable matters include representing:

  • Disney in its $85 billion acquisition of 21st Century Fox;
  • Kenvue in its pending $48.7 billion acquisition by Kimberly‑Clark and its cooperation agreement with Starboard;
  • Viacom’s transaction committee in the $30 billion merger with CBS;
  • The special committee of the board of directors of EchoStar in the $26 billion combination with DISH Network;
  • Johnson & Johnson in its $16.6 billion acquisition of Abiomed, its $14.6 billion acquisition of Intra‑Cellular Therapies, its $6.5 billion acquisition of Momenta, its pending $3.05 billion acquisition of Halda Therapeutics, the $2.1 billion sale of LifeScan to Platinum Equity, its $2 billion acquisition of Ambrx and Janssen’s $750 million acquisition of bermekimab from XBiotech;
  • CyrusOne in its $15 billion acquisition by KKR and Global Infrastructure Partners;
  • Aon in its $13 billion acquisition of NFP;
  • Amazon in its $8.45 billion acquisition of MGM;
  • AmerisourceBergen in its $6.5 billion acquisition of Walgreens’ Alliance Healthcare businesses;
  • Cano Health shareholders, including members of management, in the $4.4 billion SPAC merger with Jaws Acquisition Corp., including an $800 million PIPE investment;
  • Thermo Fisher Scientific in its $3.1 billion acquisition of Olink;
  • Consolidated Communications’ special committee in the $3.1 billion acquisition by Searchlight and BCI;
  • Radius Global Infrastructure in its $3 billion acquisition by EQT Active Core Infrastructure and PSP Investments;
  • Roivant Sciences in its $3 billion Strategic Alliance with Sumitomo Dainippon Pharma;
  • IBM in its €2.13 billion acquisition of the StreamSets and webMethods platforms from Software AG;
  • Star Bulk in its $2.1 billion combination with Eagle Bulk Shipping;
  • FactSet in its $1.925 billion acquisition of CUSIP Global Services from S&P Global, its $246.5 million acquisition of LiquidityBook and its acquisition of Irwin;
  • OneBeacon Insurance and White Mountains Insurance in the $1.7 billion sale of OneBeacon Insurance to Intact Financial;
  • Ashland in the $1.65 billion sale of its performance adhesives business to Arkema and the sale of its nutraceuticals business to Turnspire Capital Partners;
  • ADT in its $1.2 billion equity investment from State Farm;
  • Sobi in its $915 million acquisition of Dova;
  • Light & Wonder in its $850 million acquisition of Grover Charitable Gaming;
  • Pitney Bowes in the $700 million sale of its Software Solutions business to Syncsort;
  • Prosus in its $500 million PIPE investment in connection with Churchill II SPAC’s $1.5 billion merger with Skillsoft and acquisition of Global Knowledge;
  • US Foods in its $500 million convertible preferred equity investment from KKR;
  • BAF in Lindsay Goldberg’s sale of BAF to Madison IAQ;
  • Costamare in the spin-off of Costamare Bulkers;
  • Evergy in its agreements with Elliott Management and Bluescape Energy Partners;
  • GasLog Ltd. in its acquisition of GasLog Partners and its take‑private transaction with BlackRock’s Global Energy & Power Infrastructure Fund;
  • J.D. Power in its sale to Thoma Bravo;
  • Jefferies in the significant expansion of its Global Strategic Alliance with SMBC Group—which includes a joint venture combining their Japanese equities and ECM businesses, and an increase in SMBC’s equity ownership in Jefferies to up to 20%—and in the previous expansion that included a total commitment of up to $3.4 billion to Jefferies by SMBC;
  • KKR’s board committee in KKR’s conversion to a corporation; 
  • Montana Technologies in its joint venture with GE Vernova; and 
  • Univision in its sale of a majority stake to Searchlight and ForgeLight.

Mr. Baek has been included among Bloomberg Law’s “40 Under 40” in 2025 and he has been recognized for his work in mergers and acquisitions by IFLR1000. He has also been recognized by Lawdragon as among the “500 Leading Lawyers in America” and the “500 Leading Dealmakers in America.”

Mr. Baek is from Seoul, Republic of Korea. He received an A.B. cum laude from Harvard College in 2008 and a J.D. from Harvard Law School in 2015.

Mr. Baek joined Cravath in 2015 and was elected a partner in 2022. Prior to joining Cravath, he served as an officer in the Republic of Korea Air Force, including at the Air Force Operations Command and the Ministry of National Defense.

Education

  • J.D., 2015, Harvard Law School
  • A.B., 2008, Harvard College
    cum laude

Admitted In

  • New York

Rankings

Bloomberg Law

  • They’ve Got Next: The 40 Under 40 (2025)

IFLR1000

  • Mergers and Acquisitions - US (2025)

Lawdragon

  • 500 Leading Lawyers in America (2025)
  • 500 Leading Dealmakers in America (2025, 2024)
  • 500 X – The Next Generation (2025, 2024, 2023)

Deals & Cases

November 17, 2025

Johnson & Johnson’s $3.05 Billion Acquisition of Halda Therapeutics OpCo, Inc.

On November 17, 2025, Johnson & Johnson announced it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc., a clinical‑stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTACTM) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. Cravath is representing Johnson & Johnson in connection with the transaction.

Deals & Cases

November 03, 2025

Kenvue’s $48.7 Billion Acquisition by Kimberly‑Clark

On November 3, 2025, Kenvue Inc. (“Kenvue”), a global consumer health leader, and Kimberly‑Clark Corporation (“Kimberly‑Clark”), a global personal care leader, announced an agreement under which Kimberly‑Clark will acquire all of the outstanding shares of Kenvue common stock in a cash and stock transaction that values Kenvue at an enterprise value of approximately $48.7 billion, based on the closing price of Kimberly‑Clark common stock on October 31, 2025. Under the terms of the agreement, which has been unanimously approved by each company’s Board of Directors, Kenvue shareholders will receive $3.50 per share in cash as well as 0.14625 Kimberly‑Clark shares for each Kenvue share held at closing. Upon closing of the transaction, current Kenvue shareholders are expected to own approximately 46% and current Kimberly‑Clark shareholders are expected to own approximately 54% of the combined company on a fully diluted basis. Cravath is representing Kenvue in connection with the transaction.

Deals & Cases

September 22, 2025

Jefferies and SMBC Group’s Significant Expansion of Global Strategic Alliance

On September 19, 2025, Jefferies Financial Group, Inc. (“Jefferies”) and Sumitomo Mitsui Financial Group, Inc., Sumitomo Mitsui Banking Corporation and SMBC Nikko Securities Inc. (collectively, “SMBC Group”) announced they are significantly expanding their Global Strategic Alliance. This will include a joint venture to combine their Japanese equities and ECM businesses. As part of this expansion, SMBC intends to increase its equity ownership in Jefferies to up to 20% in the open market. Cravath is representing Jefferies in connection with the transactions.

Deals & Cases

May 07, 2025

Costamare’s Spin‑Off of Costamare Bulkers

On May 7, 2025, Costamare Inc. (“Costamare”) announced that it has completed the spin‑off of its dry bulk business into a standalone public company, Costamare Bulkers Holdings Limited (“Costamare Bulkers”). Each holder of Costamare common shares received one common share of Costamare Bulkers for every five Costamare common shares held as of the close of business on April 29, 2025. Cravath represented Costamare in connection with the transaction.

Deals & Cases

February 18, 2025

Light & Wonder’s Acquisition of Grover Gaming’s Charitable Gaming Assets

On February 18, 2025, Light & Wonder, Inc. (“Light & Wonder”), the leading cross‑platform global games company, announced that it has entered into a definitive agreement to acquire the charitable gaming assets of Grover Gaming, Inc. and G2 Gaming, Inc. (together, “Grover Gaming”), a leading provider of electronic pull‑tabs for charitable gaming in the U.S., for total consideration of $850 million cash, subject to customary purchase price adjustments, and a four‑year revenue based earn‑out of up to $200 million cash. Cravath is representing Light & Wonder in connection with the transaction.

Activities

August 21, 2025

Jin Baek Featured in Bloomberg Law’s 2025 “They’ve Got Next: 40 Under 40” Series

On August 12, 2025, Cravath partner Jin‑Kyu Baek was featured in Bloomberg Law’s “They’ve Got Next: 40 Under 40” series, which recognizes young lawyers who are “raising the bar in the legal profession,” based on their work on key client matters, assumption of leadership roles, pro bono commitments and more.

Activities

April 17, 2024

Jin-Kyu Baek Named a 2024 LCLD Fellow

Cravath partner Jin‑Kyu Baek was selected to join the 2024 Leadership Council on Legal Diversity (LCLD) Fellows Program. The LCLD, which was founded in 2009 as an organization of chief legal officers and law firm managing partners committed to creating a more diverse and inclusive legal profession, selects attorneys “who have shown promising leadership potential” to participate in the Fellows Program, which is a year‑long, multi‑tiered professional development series that involves personal development opportunities, leadership training, and relationship‑building resources.

Cravath Bicentennial

Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.

Explore

Cravath, Swaine & Moore LLP Logo
  • CONTACT US
  • OUR STORY
  • ALUMNI PORTAL
  • DISCLAIMERS & NOTICES

Attorney Advertising. ©2025 Cravath, Swaine & Moore LLP.